Showing results (51-60 of 182) with videos related to
Sort By:
Pageof 19
Yonsei Medical Journal|February 29, 2008
Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphomaKwang Min Kim, Ho-Cheol Kim, Kyung-Nyeo Jeon, et al.American Journal of Clinical Oncology|January 1, 2010
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimenSeok Hyun Kim, Gyeong-Won Lee, Se Il Go, et al.Yonsei Medical Journal|November 3, 2009
Successful treatment of syncope with chemotherapy irresponsive to cardiac pacemaker in head and neck cancerJi Hyun Ju, Myoung Hee Kang, Hoon Gu Kim, et al.The Oncologist|December 11, 2012
Access to palliative care among patients treated at a comprehensive cancer centerDavid Hui, Sun-Hyun Kim, Jung Hye Kwon, et al.Journal of Pain and Symptom Management|November 25, 2015
Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control StudiesGyeong-Won Lee, Rock Bum Kim, Se Il Go, et al.Journal of Pain and Symptom Management|December 6, 2012
Targeted agent use in cancer patients at the end of lifeDavid Hui, Meghan Sri Karuturi, Kimberson Cochien Tanco, et al.Journal of Cachexia, Sarcopenia and Muscle|October 22, 2021
Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphomaSe-Il Go, Mi Jung Park, Sungwoo Park, et al.Cancer Research and Treatment|July 1, 2020
Choosing Wisely: The Korean Perspective and Launch of the 'Right Decision in Cancer Care' InitiativeJoo-Young Kim, Kyoung Eun Lee, Kyubo Kim, et al.Journal of Palliative Medicine|June 6, 2012
Development and cross-validation of the in-hospital mortality prediction in advanced cancer patients score: a preliminary studyDavid Hui, Kelly Kilgore, Bryan Fellman, et al.Investigational New Drugs|May 16, 2009
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancerSung Yong Oh, Hyun Jin Kim, Tae Hyo Kim, et al.Pageof 19